By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Rue Pierre et Marie Curie BP 28262
Cedex  Labège-Innopole  31682  France
Phone: 33-5-6128-7060 Fax: 33-5-6128-7069


Company News
Genticel Receives FDA Clearance Of IND Application For U.S. Phase I Clinical Trial Of GTL001 (Procervix), Company's First-In-Class HPV Therapeutic Vaccine Candidate 6/16/2015 7:18:06 AM
Genticel Announces Positive Preclinical Proof Of Concept Results Of GTL002, Its New Multivalent HPV Therapeutic Vaccine Candidate Based On Company's Versatile Vaxiclase Platform 6/1/2015 9:12:44 AM
Genticel To Present Further Promising Pharmacology In-Vivo Results Of Its Phase 2 Immunotherapeutic Vaccine Candidate, GTL001 (Procervix), At AACR Annual Meeting 2015 4/20/2015 2:20:12 PM
Genticel Strengthens Management Team And Appoints Valerie Leroy As Senior Director, Corporate Communications And Investor Relations 4/10/2015 8:23:37 AM
Genticel Presents Pipeline Development At EUROGIN Congress Held In Seville, Spain – 4 To 7 February 2015 2/5/2015 11:29:29 AM
Genticel Licenses Vaxiclase Platform To Serum Institute of India, Ltd. For Use In Pertussis Vaccines 2/2/2015 11:15:33 AM
Genticel Business Update - Fourth Quarter 2014 1/27/2015 1:08:15 PM
Genticel To Continue Per Protocol Its Phase 2 Clinical Study With Procervix After 2nd Review By The DSMB 1/26/2015 1:37:50 PM
Genticel Completes Procervix Phase 2 Study Enrollment Ahead Of Schedule 11/13/2014 1:56:26 PM
Mary Tanner Appointed To Genticel’s Supervisory Board As Independently-Acting Member 9/19/2014 10:25:04 AM